Estee Lauder Analysts Cut Their Forecasts After Q4 Results

Estee Lauder Companies Inc (NYSE: EL) reported better-than-expected fourth-quarter earnings, but issued weak guidance.

Estee Lauder Companies Inc (NYSE:EL) reported better-than-expected fourth-quarter earnings, but issued weak guidance.

Estee Lauder reported fourth-quarter FY23 sales growth of 1% year-on-year to $3.61 billion, beating the analyst consensus of $3.47 billion. Adjusted EPS of $0.07 beat the analyst consensus of $(0.03).

Estee Lauder sees FY24 adjusted EPS of $3.50-$3.75, against the consensus of $4.83. EL sees FY24 sales growth of 5% – 7%. The company expects first-quarter FY24 adjusted EPS of $(0.31) – $(0.21) against the consensus of $0.99. Q1 FY24 revenue to decline 12% – 10%.

The company’s shares fell 3.3% to close at $156.69 on Friday.

These analysts made changes to their price targets on Estee Lauder following earnings announcement.

Telsey Advisory Group cut the price target on Estee Lauder from $250 to $210. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating.

Raymond James slashed the price target on Estee Lauder from $220 to $195. Raymond James analyst Olivia Tong maintained a Strong Buy rating.

Citigroup lowered the price target on Estee Lauder from $195 to $165. Citigroup analyst Filippo Falorni maintained a Neutral rating.

Check This Out: Napco Security Technologies And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

Total
0
Shares
Related Posts
Read More

AstraZeneca, Swedish Orphan Biovitrum And Sanofi Have Updated And Simplified Their Contractual Arrangements Relating To The Development And Commercialization Of Nirsevimab In The US

AstraZeneca, Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given the upcoming launch of nirsevimab in the US and other markets, simplification of the prior arrangements clarifies the roles and responsibilities of relevant parties.   

AZN